Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study

BACKGROUND: Everolimus is an oral inhibitor of mammalian target of rapamycin, approved for metastatic renal cell carcinoma (mRCC). Recently, personalized medicine through therapeutic drug monitoring (TDM) is recommended in cancer therapy. In this study, the relationship between everolimus blood conc...

Descripción completa

Detalles Bibliográficos
Autores principales: Takasaki, Shinya, Yamaguchi, Hiroaki, Kawasaki, Yoshihide, Kikuchi, Masafumi, Tanaka, Masaki, Ito, Akihiro, Mano, Nariyasu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413453/
https://www.ncbi.nlm.nih.gov/pubmed/30906563
http://dx.doi.org/10.1186/s40780-019-0135-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413453/
https://www.ncbi.nlm.nih.gov/pubmed/30906563
http://dx.doi.org/10.1186/s40780-019-0135-5

Ejemplares similares